PLX: Secarna's Antisense Oligonucleotide Discovery Collaboration [Yahoo! Finance]
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement [Yahoo! Finance]
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
Protalix BioTherapeutics (NYSE:PLX) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results